CHALFONT, PA – November 8, 2012 – Genomind, a personalized medicine company for neuropsychiatry, is excited to announce that company representatives will be attending and exhibiting at the American Psychiatric Nurses Association Annual Conference and the U.S. Psychiatric and Mental Health Congress, two respected conventions of mental health professionals that will occur this November.

Genomind will be on hand to share the most recent research and advancements in the field of personalized medicine, including their groundbreaking Genecept™ Assay, a saliva-based test that quickly identifies biomarkers and genes that may influence or assist a clinician in developing a treatment plan for patients with depression and other neurological disorders. Genomind staff will share information with attendees on how such tests can be implemented into their practices, as well as how use of the test can often lead to better patient outcomes.

The American Psychiatric Nurses Association Annual Conference runs from November 7-10, 2012, at the David L. Lawrence Convention Center in Pittsburgh. The U.S. Psychiatric and Mental Health Congress will take place November 8-11, 2012, at the San Diego Convention Center.

About Genomind

Genomind is a personalized medicine company, comprised of innovative researchers and expert leaders in psychiatry and neurology. Genomind is committed to discovery of the underlying causes of neuropsychiatric disorders and supports the development of personalized medicine that improves patients’ lives. Genomind was founded by Ronald I. Dozoretz, MD, a psychiatrist who has devoted his career to improving mental health. Jay Lombard, DO, a neurologist and co-founder of Genomind, is a critically acclaimed author and nationally recognized thought leader in neuropsychiatry practice and research.